Xiang M, et al. - In patients with locoregionally advanced (American Joint Committee on Cancer stage III-IVB) squamous cell carcinomas of the oropharynx, larynx, or hypopharynx, cisplatin and cetuximab were compared in terms of efficacy as concurrent therapies with radiation (RT). Overall, 1395 patients participated, of whom 786 (56%) were given cisplatin and 609 (44%) received cetuximab; median follow-up of 3.5 years was performed in the patients who remained alive. Participants were identified in the Surveillance, Epidemiology, and End Results-Medicare database and were examined using filtering, propensity score matching, and multivariable Fine-Gray regression to adjust for differences in age, comorbidity, and cycles of systemic therapy received. In the cetuximab cohort vs cisplatin cohort, a remarkably higher cancer-specific mortality (CSM) (39% vs 25% at 3 years) as well as less dysphagia, more dermatitis, and a similar incidence of mucositis were observed. Overall, cisplatin could be preferred over cetuximab in this setting.